UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 12b-25
                           NOTIFICATION OF LATE FILING

                       Commission File Number: 33-25126-D

                  |_| Form 10-K |_| Form 20-F |_| Form 11-K
                  |X| Form 10-Q |_| Form 10-D |_| Form N-SAR
                                |_| Form N-CSR

                        For Period Ended: March 31, 2006

|_| Transition Report on Form 10-K |_| Transition Report on Form 20-F
|_| Transition Report on Form 11-K |_| Transition Report on Form 10-Q
|_| Transition
Report on Form N-SAR For the Transition Period Ended:

Nothing  in this  form  shall be  construed  to imply  that the  Commission  has
verified any information contained herein.

If the notification  relates to a portion of the filing checked above,  identify
the Item(s) to which the notification relates: Not applicable

                         PART I - REGISTRANT INFORMATION

Full Name of Registrant: Medefile International, Inc.
Former Name if Applicable: Omnimed International, Inc.
Address of Principal Executive Office: 2 Ridgedale Avenue - Suite 217,
                                       Cedar Knolls, New Jersey 07927

                        PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without  unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed (Check box if appropriate).



     (a)  The reasons  described in  reasonable  detail in Part III of this form
          could not be eliminated without unreasonable effort or expense;
|X|  (b)  The subject annual report,  semi-annual  report,  transition report on
          Form 10-K,  Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion
          thereof,  will be  filed  on or  before  the  fifteenth  calendar  day
          following the prescribed due date; or the subject  quarterly report or
          transition report on Form 10-Q or subject  distribution report on Form
          10-D,  or  portion  thereof,  will be filed  on or  before  the  fifth
          calendar day following the prescribed due date; and
     (c)  The accountant's statement or other exhibit required by Rule 12b-25(c)
          has been attached if applicable.


                              PART III - NARRATIVE

State below in reasonable  detail the reasons why Forms 10-K,  20-F, 11-K, 10-Q,
10-D, N-SAR , N-CSR or the transition  report or portion  thereof,  could not be
filed within the prescribed period.

The  registrant  is in the process of  preparing  and  reviewing  the  financial
information of the Company on a consolidated basis. The process of compiling and
disseminating the information required to be included in the Form 10-QSB for the
relevant fiscal quarter, as well as the completion of the required review of the
Company's financial  information on a consolidated basis, could not be completed
without  incurring  undue hardship and expense.  The  registrant  undertakes the
responsibility  to file such quarterly  report no later than five days after its
original date.

                           PART IV - OTHER INFORMATION

(1)  Name  and  telephone  number  of  person  to  contact  in  regard  to  this
notification: Milton Hauser, President: (973) 993-8001.

(2) Have all other  periodic  reports  required under Section 13 or 15(d) of the
Securities  Exchange Act of 1934 or Section 30 of the Investment  Company Act of
1940  during  the  preceding  12  months  or for such  shorter  period  that the
registrant was required to file such report(s) been filed?  If the answer is no,
identify report(s). |X| Yes |_| No

(3) Is it anticipated that any significant  change in results of operations from
the  corresponding  period for the last  fiscal  year will be  reflected  by the
earnings statements to be included in the subject report or portion thereof? |_|
Yes |X| No

If so, attach an explanation of the  anticipated  change,  both  narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

Medefile  International  has caused this notification to be signed on its behalf
by the undersigned thereunto duly authorized.




Date: May 15, 2006                   Medefile International, Inc.

                                     By:  /s/ Milton Hauser
                                          --------------------------------------
                                          Milton Hauser, President